Use of ALA and ALA derivatives for optimizing ALA-based photodynamic therapy: A review of our experience

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 25, Issue 1-2, 2006, Pages 127-143

  Fukuda, Haydée ^a   Casas, Adriana ^a   Batlle, Alcira ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

5 aminolevulinic acid; ALA esters; Photodynamic therapy; Porphyrins protoporphyrin IX

Indexed keywords

1,10 PHENANTHROLINE; 1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; AMINOLEVULINIC ACID; CHELATING AGENT; DEFEROXAMINE; DIMETHYL SULFOXIDE; DRUG VEHICLE; EDETIC ACID; ESTERASE; HEME; LIPOSOME; LIVER ENZYME; PHTHALOCYANINE ALUMINUM; PORPHOBILINOGEN; PORPHYRIN; PRODRUG; PROTOPORPHYRIN;

BARRETT ESOPHAGUS; BREAST ADENOCARCINOMA; BREAST TUMOR; CANCER CELL; CANCER DIAGNOSIS; COLLOID; COLON ADENOCARCINOMA; COLORECTAL CANCER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; ENZYME BLOOD LEVEL; EXPLANT; FEEDBACK SYSTEM; FLUORESCENCE; HUMAN; LIGHT EXPOSURE; LOTION; LUNG CANCER; MOUTH LESION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; PHOTOSENSITIVITY; PHOTOTHERAPY; PORPHYRIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN TUMOR; SOLID TUMOR; TUMOR GROWTH;

EID: 33644766068     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.70     Document Type: Review

References (96)

1. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998; 90:889-905.
2. Raab O. Ueber die Eirkun fluorescierender Stoff auf Infusorien. Z Biol 1900; 39:524.
3. von Tappein H, Jesionek A. Therapeutische Versuche mit fluoreszierende Stoffen. Munch Med Bochenschr 1903; 50:2404.
4. Diamond I, McDonagh AF, Wilson CB, Granelli SL, Nielsen S, Jaenicke R. Photodynamic therapy of malignant tumors. Lancet 1972; 2:1175-1177.
5. Gudgin Dickison EF, Goyan RL, Pottier RH. New directions in photodynamic therapy. Cell Mol Biol 2002; 48:939-954.
6. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002; 66:89-106.
7. Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer 1987; 56:589-595.
8. Fukuda H, Paredes SR, Batlle AM del C. Tumor localizing properties of porphyrins. In vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms. Drug Des Deliv 1989; 5:133-139.
9. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6:143-148.
10. Batlle AM del C. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B 1993; 20:5-25
11. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinical useful photosensitiser for photodynamic therapy. J Photochem Photobiol B 1992; 14:275-292.
12. Fukuda H, Paredes SR, Batlle AM del C. Tumor-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp Biochem Physiol 1992; 102B:433-436.
13. Batlle AM del C, Llambías EBC, Wider de Xifra E, Tigier H. Porphyrin biosynthesis in the soybean callus tissue system XV. The effect of growth conditions. Int J Biochem 1975; 6:591-606.
14. Malik Z, Djaldetti M. 5-aminolevulinic acid stimulation of porphyrins and hemoglobin synthesis by uninduced Friend erythrocyte leukemia cells. Cell Diff 1979; 8:223-225.
15. Sima AAF, Kennedy JC, Blakeslee D, Robertson DM. Experimental porphyrinopathy: a preliminary report. Can J Neurol Sci 1981; 8:105-113.
16. Daily HA, Smith A. Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochem J 1986; 223:441-445.
17. Stout DL, Becker FF. Heme enzymes patterns in rat liver nodules and tumors. Cancer Res 1987; 47:963-969.
18. Schoenfeld N, Mamet R, Leibovici L, Lahav M, Lurie Y, Atsmon A. The heme biosynthetic pathway in the regenerating rat liver. The relation between enzymes of heme synthesis and growth. Eur J Biochem 1987; 166:663-666.
19. Schoenfeld N, Epstein M, Lahav M, Mamet R, Shaklai M, Atsmon A. The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders. Cancer Lett 1988 43:43-48.
20. El-Sharabasy MMH, El-Wassel AM, Hefez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992; 65:409-412.
21. Lahav M, Epstein O, Schoenfeld N, Shakali M, Atsmon A. Increased porhobilinogen deaminase activity in patients with malignant lymphoproliferative diseases. J Am Med Assn 1987; 257:39-42.
22. Navone NM, Polo C, Frisardi A, Batlle AM del C. Mouse mammary carcinoma PBGase and hydroxymethylbilane synthetase. Comp Biochem Physiol B 1991; 98:67-71.
23. Schoenfeld N, Mamet R, Leibovici L, Epstein M, Teitz Y, Atsmon A. Growth rate determines activity of PBG deaminase in non-malignant and malignant cells. Biochem Med Metab Biol 1988; 40:213-217.
24. Gibson, SL, Cupriks DJ, Havens JJ, Nguyen M, Hilf R. A regulatory role for porphobilinogen deaminase (PBGD) in δ-aminolaevulinic acid (δ-ALA)-induced photosensitization? Br J Cancer 1998; 77:235-243.
25. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstadter F, Hofstetter A. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994; 44:836-841.
26. Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolevulinic acid. Br J Urol 1999; 83:129-135.
27. Filbeck T, Wimmershoff B, Pichlmeier U, Karrer S, Wieland WF, Szeimies RM, Rossler W. No generalized skin phototoxicity after intravesical application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer. Urol Int 200; 64:126-128.
28. Hillemanns P, Weingandt H, Stepp H, Baumgartner R, Xiang W, Korell M. Assessment of 5-aminolevulinic acid induced porphyrin fluorescence in patients with peritoneal endometriosis. Am J Obstet Gynecol 2000; 183:52-57.
29. Mayinger B, Reh H, Hochberger J, Hahn EG. Endoscopic photodynamic diagnosis: oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions Gastrointest Endosc 1999; 50:242-246.
30. Baumgartner R, Huber RM, Schulz H, Stepp H, Rick K, Gamarra F, Leberig A, Roth C. Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J Photochem Photobiol B 1996; 36:169-174.
31. Ladner DP, Steiner RA, Allemann J, Haller U, Walt H. Photodynamic diagnosis of breast tumours after oral application of aminolevulinic acid. Br J Cancer 2002; 84:33-37.
32. Fukuda H, Casas A, Chueke F, Paredes SR, Batlle AM del C. Photodynamic action of endogenously synthesized porphyrins from aminolevulinic acid, using a new model for assaying the effectiveness of tumoral cell killing. Int J Biochem 1993; 25(10):1395-1398.
33. Fukuda H, Batlle AM del C, Riley PA. Kinetics of porphyrin accumulation in cultured epithelial cells exposed to aminolevulinic acid. Int J Biochem 1993; 25:1395-398.
34. Washbrook R, Fukuda H, Batlle AM del C, Riley PA. Stimulation of tetrapyrrole synthesis in mammalian epithelial cells in culture by exposure to aminolevulinic acid. Br J Cancer 1997; 75(3):381-387.
35. Schoenfeld N, Mamet R, Nordenberg Y, Shafran M, Babushkin T, Malik Z. Protoporphyrin biosynthesis in melanoma B16 cells stimulated by 5-aminolevulinic acid and chemical inducers: characterization of photodynamic inactivation. Int J Cancer 1994; 56:106-112.
36. Peng Q, Evensen JF, Rimington C, Moan J. A comparison of different photosensitizing dyes with respect to uptake in C3H tumors and tissues of mice. Cancer Lett 1987; 36:1-10.
37. Divaris DXG, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicle of mice after systemic administration of 5-aminolevulic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990; 136:891-897.
38. Bedwell J, MacRobert AJ, Phillips D, Bown SG. Fluorescence distribution and photodynamic effect of ALA-induced protoporphyrin IX in the DMH rat colonic tumor model. Br J Cancer 1992; 65:818-824.
39. Loh CS, Bedwell J, MacRobert AJ, Krasner N, Phillips D & Bown SG. Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phtalocyanine and 5-aminolevulinic acid. Br J Cancer 1992; 66: 452-462.
40. Loh C, MacRobert AJ, Regula J, Bown SG. Oral vs i.v. administration of 5-ALA. Br J Cancer 1993; 68:41-51.
41. Fukuda H, Paredes SR, Casas A, Chueke F, Batlle AM del C. Potential of liposome entrapped aminolevulinic acid in cancer therapy. Effect of prior injection of empty liposomes and different routes of administration. Cancer J 1992; 5:295-299.
42. Whitney D, Tope E, Ross V, Kollias N, Martin A, Gillies R, Anderson RR. Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid. Photochem Photobiol 1998; 67:249-255.
43. Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG. Photodynamic therapy of oral cancer: photosensitization with systemic aminolaevulinic acid. Lancet 1993; 342:147-148.
44. Ackroyd R, Brown NJ, Vernon DI, Roberts DJH, Stephenson TJ, Marcus SL, Stoddard CJ, Reed MWR. 5-aminolevulinic acid photosensitization of dysplastic Barret's esophagus: a pharmacokinetic study. Photochem Photobiol 1999; 70:656-662
45. Szeimies RM, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 1996; 192:246-251.
46. Mustajoki P, Timonen K, Gorchein A, Seppalainen AM, Matikainen E, Tenhunen R. Sustained high plasma 5-aminolevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest 1992; 22:407-411.
47. Fukuda H, Casas A, Batlle A. Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy. Int J Biochem Cell Biol 2005; 37:272-276.
48. Bretshko E, Szeimies RM, Landthaler M, Lee G. Topical 5-minolevulinic acid for photodynamic therapy of basal cell carcinoma. Evaluation of stratum corneum permeability in vitro. J Control Release 1996; 42:203-208.
49. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epitelial skin tumors using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol 1995; 133:282-288.
50. Malik Z, Kostenich G, Roitman B, Ehrenberg B, Orenstein A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumors of mice. J Photochem Photobiol B 1995; 28:213-218.
51. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolevulinic acid treated cells. Br J Cancer 1996; 74:688-697.
52. Chang SC, MacRobert AJ, Porter JB, Bown SG. The influence of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolevulinic acid administration: an in vivo study. J Photochem Photobiol B 1997; 38:114-122.
53. DeRosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley MVLB. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release 2000; 65:359-366.
54. Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell carcinoma using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998; 197:248-254.
55. Vonarx V, Eleouet S, Carre J, Ioss P, Gouyette A, Leray AM, Merle C, Lajat Y, Patrice T. Potential efficacy of a delta 5-aminolevulinic acid bioadhesive gel formulation for the photodynamic treatment of lesions of the gastrointestinal tract in mice. J Pharm Pharmacol 1997; 49:652-656.
56. Lieb S, Szeimies RM, Lee G. Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. Eur J Pharm Biopharm 2002; 53:99-106.
57. Stenzl A, Eder I, Kostron H, Klocker H, Bartsch G. Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolevulinic acid (delta-ALA) for superficial bladder cancer. J Photochem Photobiol B 1996; 36:233-236.
58. Rhodes LE, Tsoukas MM, Anderson RR, Kollias M. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J Invest Dermatol 1997; 108:7-91.
59. Casas A, Fukuda H, Batlle AM del C. Tissue distribution and kinetics of endogenous porphyrins synthesized after topical application of ALA in different vehicles. Br J Cancer 1999; 81(1):13-18.
60. Stoughton R, Fritsch W. Influence of dimethylsulfoxide (DMSO) on human percutaneous absorption. Arch Dermatol 1964; 90:512-517.
61. Casas A, Fukuda H, Di Venosa G, Batlle AM del C. The influence of the vehicle on the synthesis of porphyrins after topical application of ALA. Implications in cutaneous photodynamic sensitization. Br J Dermatol 2000; 143:1-10.
62. Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, Giercksky KE. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62:906-913.
63. Fujita H, Yamamoto M, Yamagami T, Hayashi N, Bishop TR, DeVerneuil H, Yoshinaga T, Shibahara S, Morimoto R, Sassa S. Sequential activation of genes for heme pathway enzymes during erythroid differentiation of mouse Friend-virus transformed erythroleukemia cells. Biochim Biophys Acta 1991; 1090:311-316.
64. Casas A, Fukuda H, Meiss R, Batlle AM del C. Topical and intratumoural photodynamic therapy with 5-aminolevulinic acid in a subcutaneous murine mammary adenocarcinoma. Cancer Letters 1999; 141:29-38.
65. Casas A, Batlle A. Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy. Curr Med Chem Anti-Cane Agents 2002; 2:465-475.
66. Lopez RFV, Lange N, Guy R, Bentley MVLB. Photodynamic of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 2004; 56:77-94.
67. Kloek J, Beijersbergen van Henegouwen JMJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 1996; 64:994-1000.
68. Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjorseth A, Nesland JM. Build-up of esterified aminolevulinic acid derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996; 34:95-96.
69. Gaullier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LW, Moan J. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 1997; 57:1481-1486.
70. Brunner H, Hausmann F, Krieg RC, Endlicher E, Scholmerich J, Knuechel R, Messmann H. The effects of 5-aminolevulinic acid esters on protoporphyrin IX production in human adenocarcinoma cell lines. Photochem Photobiol 2001; 74(5):721-725.
71. Washbrook R, Riley PA. Comparison of delta-aminolevulinic acid and its methyl ester as an inducer of porphyrin synthesis in cultured cells. Br J Cancer 1997; 75:1417-1420.
72. Kloek J, Akkermans W, Van Henegouwen GMJB. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 1998; 67:150-154.
73. Casas A, Fukuda H, Di Venosa G, Batlle A. Photosensitisation and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer 2001; 85:279-284.
74. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, Kucera P, Wagnieres G, van den Bergh H. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999; 80:185-193.
75. Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, van den Bergh H, Lange N. 5-aminolevulinic acid and its derivatives :physical chemical proterties and protoporphyrin IX: formation in cultured cells. J Photochem Photobiol B 2000; 54:72-78.
76. Tunstall RG, Barnett AA, Schofield J, Griffiths J, Vernon DI, Brown SB, Roberts DJ. Porphyrin accumulation induced by 5-aminolevulinic acid esters in tumor cells growing in vitro and in vivo. Br J Cancer 2002; 87:246-250.
77. Ren QG, Wu SM, Peng Q, Chen JY. Comparison of 5-aminolevulinic acid and its hexylester mediated photodynamic action on human hepatoma cells. Acta Biochim Sin 2002; 34(5):650-654.
78. Casas A, Batlle AM, Butler AR, Robertson D, Brown EH, MacRobert AJ, Riley PA. Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. Br J Cancer 1999; 80:1525-1532.
79. Casas A, Perotti C, Sacolitti M, Sacca P, Fukuda H, Batlle AM. ALA and ALA-hexyl ester in free and liposomal formulations for the photosensitization of tumour organ cultures. Br J Cancer 2002; 86:837-842.
80. Casas A, Perotti C, Fukuda H, Rogers L, Butler AR, Batlle A. ALA and ALA hexylester-induced porphyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving photosensitization. Br J Cancer 2001; 85(11):1794-1800.
81. Perotti C, Casas A, Fukuda H, Sacca P, Batlle A. Topical application of ALA and ALA hexyl ester on a subcutaneous mammary adenocarcinoma: tissue distribution. Br J Cancer 2003; 88:432-437.
82. Moan J, Ma L, Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer 2001; 92:139-143.
83. Van den Akker JT, Iani V, Star WM, Sterenborg HJ, Moan J. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 2000; 72:681-689.
84. Perotti C, Casas A, Fukuda H, Sacca P, Batlle A. ALA and ALA hexyl ester induction of porphyrins after their systemic administration to tumour bearing mice. Br J Cancer 2002; 87:790-795 .
85. Perotti C, Fukuda H, DiVenosa G, Mac Robert A, Batlle A, Casas A. Porphyrin synthesis from ALA derivatives in photodynamic therapy. In vitro and in vivo studies. Br J Cancer 2004; 90:1660-1665 .
86. Eleouet S, Rousset N, Carré J, Bourré L, Vonarx V, Lajat Y, Beijersbergen van Henegouwen G, Patrice T. In vitro fluorescence, toxicity and phototoxicity induced by 5-aminolevulinic acid (ALA) or ALA esters. Photochem Photobiol 2000; 71:447-454.
87. DiVenosa G, Fukuda H, Batlle A, Casas A. A simple method for separating ALA derivatives using ionic exchange chromatography. J Photochem Photobiol 2004; 75:157-163.
88. Juzeniene A, Ma LW, Juzenas P, Iani V, Lange N, Moan J. Production of protoporphyrin IX from 5-aminolevulinic acid and two of its esters in cells in vitro and in tissues in vivo. Cell Mol Biol 2002; 48(8):911-916.
89. Ninomiya N, Itoh Y, Tajima S Ishibashi A. In vitro and in vivo expression of protoporphyrin IX induced by lipophilic 5-aminolevulinic acid derivatives. J Dermatol Sci 2001; 27:114-120.
90. Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C. Synthesis and biological studies of 5-aminolevulinic acid containing dendrimers for photodynamic therapy. Bioconjug Chem 2001; 12:980-988.
91. DiVenosa G, Casas C, Battah S, Dobbin P, Fukuda H, MacRobert A, Batlle A. Investigation of a novel dendritic derivative of aminolevulinic acid for photodynamic therapy. Int J Biochem Cell Biol 2005 (in press).
92. Rud E, Gederaas O, Hogset A, Berg K. 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2000; 71:640-647.
93. Bermúdez Moretti M, Correa García SR, Perotti C, Batlle A, Casas A. Aminolevulinic acid transport in murine mammary adenocarcinoma cells is mediated by beta transporters. Br J Cancer 2002; 87:471-474.
94. Howard J, Vernon D, Brown S, Berg K. Tetrapyrrole Discussion Group Meeting 2000.
95. Gederaas O, Holroyd A, Beown S, Vernon D, Moan J, Berg K. 5-aminolevulinic acid methyl ester transport on aminoacid carriers in a human colon adenocarcinoma cell line. Photochem Photobiol 2002; 73:164-169.
96. Whitaker CJ, Battah SH, Forsyth MJ, Edwards C, Boyle RW, Matthews EK. Photosensitization of pancreatic tumour cells by delta-aminolevulinic acid esters. Anticancer Drug Des 2000; 15:161-170.